Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by First Bank & Trust

First Bank & Trust boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 51,929 shares of the biopharmaceutical company’s stock after acquiring an additional 354 shares during the quarter. Gilead Sciences comprises about 0.9% of First Bank & Trust’s portfolio, making the stock its 18th largest position. First Bank & Trust’s holdings in Gilead Sciences were worth $4,797,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Advyzon Investment Management LLC purchased a new position in shares of Gilead Sciences during the 4th quarter valued at about $418,000. Handelsbanken Fonder AB raised its stake in shares of Gilead Sciences by 9.6% during the 4th quarter. Handelsbanken Fonder AB now owns 590,156 shares of the biopharmaceutical company’s stock valued at $54,513,000 after buying an additional 51,453 shares during the last quarter. Sunpointe LLC raised its stake in shares of Gilead Sciences by 12.0% during the 4th quarter. Sunpointe LLC now owns 4,654 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 500 shares during the last quarter. Global Retirement Partners LLC raised its stake in shares of Gilead Sciences by 2.2% during the 4th quarter. Global Retirement Partners LLC now owns 8,982 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 194 shares during the last quarter. Finally, Convergence Investment Partners LLC raised its stake in shares of Gilead Sciences by 15.8% during the 4th quarter. Convergence Investment Partners LLC now owns 68,447 shares of the biopharmaceutical company’s stock valued at $6,322,000 after buying an additional 9,330 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Truist Financial lifted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Piper Sandler lifted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Finally, The Goldman Sachs Group lifted their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $102.08.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $107.65 on Thursday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $107.81. The stock has a 50 day moving average of $94.70 and a two-hundred day moving average of $88.23. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market cap of $134.16 billion, a P/E ratio of 290.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts expect that Gilead Sciences, Inc. will post 7.94 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.94%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is currently 832.43%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 713,000 shares of company stock worth $67,945,181 in the last ninety days. Insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.